Tango Therapeutics, Inc. (TNGX) intrinsic value & 10-year financials
Tango Therapeutics, Inc. (TNGX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 52.1% a year to $62.4M, with an average return on invested capital of -211.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $22.04
- Market cap
- $2.6B
- Revenue (FY2025)
- $62.4M
- Revenue growth (7-yr CAGR)
- 52.1%
- ROIC (10-yr avg)
- -211.1%
- Free cash flow (FY2025)
- -$139.9M
TNGX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $62.4M | -$101.6M | -$0.87 | -$139.9M | -178.4% | -51.9% |
| FY2024 | $42.1M | -$130.3M | -$1.19 | -$132.3M | -346.1% | -75.1% |
| FY2023 | $36.5M | -$101.7M | -$1.08 | -$119.5M | -312.6% | -50.5% |
| FY2022 | $24.9M | -$108.2M | -$1.23 | -$116.8M | -446.8% | -48.5% |
| FY2021 | $37.0M | -$58.2M | -$0.94 | -$61.4M | -157.1% | -548.4% |
| FY2020 | $7.7M | -$52.0M | — | $69.0M | -681.8% | -491.9% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Tango Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Tango Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -39.4% ROIC.
Tango Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Tango Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-28.90 per share.